A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
UltraLong play
Your words are never more true, this is a frustratingly UltraLong play...but ultimately, it will be a positive one.
The final verdict is still not yet in. The FDA did not *Reject* AMPLIGEN at the end of 2009...the FDA gave one more condition in order to *APPROVE* AMPLIGEN (another study to verify efficacy)...OK what does this mean?
Bottom line: Once HEB submits the results of this next study in whatever format FDA expects, showing the results we already know it is going to show, AMPLIGEN WILL BE APPROVED! This is VERY good news.
As far as stock price, investors (rightly conservative about this volatile history) won't start their pile on until more news of a completed study with expected results is on its way to the FDA. However, if one can afford to accumulate HEB under $1 in this bad economy, I believe it will pay off eventually.
Be well and prosper